[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Falavigna A, Santos JA, Chimelli L, Ferraz FA, Bonatelli Ad Ade P: Anaplastic meningioma: case report. Arq Neuropsiquiatr; 2001 Dec;59(4):939-43
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: case report.
  • Intracranial meningiomas continue to challenge our best clinical efforts to eliminate them once discovered and deemed appropriate for treatment.
  • Malignant meningiomas constitute 10% to 15% of all meningiomas and limited information exists regarding adjuvant treatment.
  • Traditional chemotherapy has proven ineffective; thus, new chemotherapeutic agents and new methods of delivery should be developed.
  • Immunotherapy may be considered for patients with malignant meningiomas when all others previous treatment have failed.
  • We report a case of anaplastic papillary meningioma.
  • A computerized tomography and magnetic resonance image demonstrated a large left temporo-occipital mass with diffuse contrast enhancement and extensive surrounding edema.
  • The treatment was complemented by external whole brain radiation.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11733842.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 28
  •  go-up   go-down


2. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR: The treatment of malignant meningioma with verotoxin. Neoplasia; 2002 Jul-Aug;4(4):304-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of malignant meningioma with verotoxin.
  • Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate.
  • An orthotopic xenograft model was used to test the efficacy of VT1 treatment for MM.
  • We first demonstrated that Gb(3) was highly expressed by the MM cell line, IOMM-Lee, and that this cell line was highly sensitive to VT1 treatment in vitro.
  • A single intratumoral injection of VT1 significantly improved survival in nude mice harboring intracranial tumours (P<.0001).
  • VT1 treatment of MM is effective in our orthotopic xenograft model, and warrants further exploration as a potential treatment for these highly anaplastic and aggressive neoplasms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Shiga Toxin 1 / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Division / drug effects. Drug Screening Assays, Antitumor. Female. Humans. Male. Mice. Mice, Nude. Middle Aged. Neovascularization, Pathologic / drug therapy. Trihexosylceramides / analysis. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Oct 8;1455(2-3):375-86 [10571026.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2901-10 [10515895.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):345-54 [10763802.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Brain Res. 2000 Nov 10;883(1):87-97 [11063991.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Steroids. 2000 Oct-Nov;65(10-11):795-800 [11108890.001]
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):27-39 [11131984.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):551-4 [11304690.001]
  • [Cites] Microbes Infect. 2001 May;3(6):493-507 [11377211.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):99-106 [11418306.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):891-7 [11442480.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2118-25 [8297651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6996-7000 [7624357.001]
  • [Cites] J Pathol. 1996 Apr;178(4):442-6 [8691324.001]
  • [Cites] Trends Microbiol. 1996 Apr;4(4):147-53 [8728608.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2757-67 [9326243.001]
  • [Cites] Oncol Res. 1997;9(10):553-63 [9507533.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):333-40 [9689324.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):137-50 [9892096.001]
  • [Cites] Oncol Res. 1999;11(1):33-9 [10451029.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • (PMID = 12082546.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Shiga Toxin 1; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide
  • [Other-IDs] NLM/ PMC1531702
  •  go-up   go-down


3. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • Tissue factor pathway inhibitor 2 (TFPI-2) is a 32-kDa extracellular matrix-associated kunitz-type serine proteinase inhibitor.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Malignant meningiomas constitute 10-15% of all meningiomas and our previous studies revealed loss of expression of TFPI-2 in malignant gliomas.
  • To investigate the role of TFPI-2 in the invasiveness of malignant meningiomas, we stably transfected the human meningioma cell line, IOMM-Lee, with a vector capable of expressing a transcript complementary to the full length of TFPI-2 mRNA in a sense orientation.
  • Finally, TFPI-2 overexpression inhibited intracranial tumor formation in nude mice.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


Advertisement
4. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C: Meningioma. Crit Rev Oncol Hematol; 2008 Aug;67(2):153-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Meningiomas are mostly benign tumours originating from the arachnoid cap cells, represent 13-26% of all intracranial tumours.
  • Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas.
  • Complete surgical excision is the standard treatment.
  • Radiotherapy is currently used in the clinical practice in atypical, malignant or recurrent meningioma at a total dose of 45-60Gy.
  • Medical therapy for patients with recurrent, progressive and symptomatic disease after repeated surgery, radiosurgery and radiotherapy is investigational.
  • Hormonal therapy with progesterone antagonists has shown modest results, while chemotherapy with hydroxyurea appears moderately active.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342535.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 184
  •  go-up   go-down


5. Andersen C: [Intracranial meningioma. New knowledge]. Ugeskr Laeger; 2001 May 7;163(19):2618-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial meningioma. New knowledge].
  • [Transliterated title] Meningeoma intracraniale. Ny viden.
  • Meningiomas are classified according to WHO (1993), and include eleven subtypes of benign meningiomas, two semi-malignant and one anaplastic.
  • Increasing knowledge of the natural history concerning growth rate and the treatment of incidental meningiomas is accumulating.
  • Meningiomas formerly classified as surgically inaccessible are now often operable due to a continuing refinement of the surgical techniques and the study of possible new routes of intracranial tumour removal.
  • [MeSH-major] Brain Neoplasms. Meningioma
  • [MeSH-minor] Chromosome Deletion. Chromosomes, Human, Pair 22. Combined Modality Therapy. Humans. Receptors, Cell Surface / drug effects. Receptors, Cell Surface / metabolism. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11360354.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Cell Surface
  • [Number-of-references] 38
  •  go-up   go-down


6. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exenteration is indicated in patients with malignant neoplasms of orbital contents.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


7. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • The interval between the onset of the intracranial disease and the appearance of the metastasis varies from months to many years.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Goldhoff P, Warrington NM, Limbrick DD Jr, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB: Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res; 2008 Dec 1;14(23):7717-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: As favorable outcomes from malignant brain tumors remain limited by poor survival and treatment-related toxicity, novel approaches to cure are essential.
  • Here, we investigate the role of PDE4 in brain tumors and examine the utility of PDE4 as a therapeutic target.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was used to evaluate the expression pattern of a subfamily of PDE4, PDE4A, in multiple brain tumor types.
  • To determine therapeutic potential of PDE4 inhibition, Rolipram, temozolomide, and radiation were tested alone and in combination on mice bearing intracranial U87 xenografts.
  • RESULTS: We found that PDE4A is expressed in medulloblastoma, glioblastoma, oligodendroglioma, ependymoma, and meningioma.
  • Moreover, when PDE4A1 was overexpressed in Daoy medulloblastoma and U87 glioblastoma cells, in vivo doubling times were significantly shorter for PDE4A1-overexpressing xenografts compared with controls.
  • In long-term survival and bioluminescence studies, Rolipram in combination with first-line therapy for malignant gliomas (temozolomide and conformal radiation therapy) enhanced the survival of mice bearing intracranial xenografts of U87 glioblastoma cells.
  • Bioluminescence imaging indicated that whereas temozolomide and radiation therapy arrested intracranial tumor growth, the addition of Rolipram to this regimen resulted in tumor regression.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11392-9 [16357147.001]
  • [Cites] Drug Discov Today. 2005 Nov 15;10(22):1503-19 [16257373.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1666-78 [16478988.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):733-54 [16759164.001]
  • [Cites] Biochem Soc Trans. 2006 Aug;34(Pt 4):504-9 [16856845.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3799-810 [16940352.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] Curr Top Dev Biol. 2006;75:225-59 [16984814.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):651-8 [17234775.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5248-57 [17545604.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Chem Res Toxicol. 2000 Oct;13(10):944-8 [11080038.001]
  • [Cites] Cell Signal. 2001 Dec;13(12):911-8 [11728831.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28298-309 [11994273.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):268-76 [12432276.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] J Neurosurg. 1977 Apr;46(4):477-83 [191576.001]
  • [Cites] J Neurooncol. 1983;1(1):61-7 [6086852.001]
  • [Cites] Pharmacopsychiatry. 1984 Nov;17(6):188-90 [6393150.001]
  • [Cites] Biochem J. 1993 Jun 15;292 ( Pt 3):677-86 [7686364.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3058-61 [8391385.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):673-81 [7772057.001]
  • [Cites] Eur J Cancer. 1995;31A(5):714-7 [7640043.001]
  • [Cites] Biochem J. 1995 Sep 15;310 ( Pt 3):965-74 [7575434.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):161-8 [9120546.001]
  • [Cites] Neurosci Lett. 1998 Mar 6;244(1):41-6 [9578140.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):693-703 [9677330.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4733-43 [9822544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] Cell Signal. 2005 Sep;17(9):1158-73 [15905070.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1523-31 [16034090.001]
  • [Cites] Arch Toxicol. 2006 Feb;80(2):88-97 [16167140.001]
  • [Cites] Nat Methods. 2005 Aug;2(8):607-14 [16094386.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33178-89 [16030021.001]
  • [CommentIn] Clin Cancer Res. 2009 May 1;15(9):3238; author reply 3238-9 [19406836.001]
  • (PMID = 19047098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NINDS NIH HHS / NS / P30 NS057105; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R21 CA108677; United States / NCI NIH HHS / CA / P50 CA94056; United States / NCI NIH HHS / CA / P50 CA094056-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phosphodiesterase Inhibitors; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; K676NL63N7 / Rolipram
  • [Other-IDs] NLM/ NIHMS82831; NLM/ PMC2615415
  •  go-up   go-down


9. Sessums K, Mariani C: Intracranial meningioma in dogs and cats: a comparative review. Compend Contin Educ Vet; 2009 Jul;31(7):330-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma in dogs and cats: a comparative review.
  • These tumors are more likely to be malignant in dogs.
  • Surgery, radiation, and chemotherapy can target the primary tumor, whereas steroids and anticonvulsants are confined to treating secondary effects of the tumor.
  • If the meningioma cannot be resected in its entirety, radiation therapy can increase survival time.
  • [MeSH-major] Cat Diseases / diagnosis. Dog Diseases / diagnosis. Meningeal Neoplasms / veterinary. Meningioma / veterinary
  • [MeSH-minor] Animals. Breeding. Cats. Dogs. Prognosis. Risk Factors. Species Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746352.001).
  • [ISSN] 1940-8315
  • [Journal-full-title] Compendium (Yardley, PA)
  • [ISO-abbreviation] Compend Contin Educ Vet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


10. Regel JP, Schoch B, Sandalcioglu IE, Wieland R, Westermeier C, Stolke D, Wiedemayer H: Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation. Childs Nerv Syst; 2006 Feb;22(2):172-5
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation.
  • RATIONALE: Meningiomas in the pediatric age group are very rare tumors, comprising about 1-4.2% of all primary pediatric intracranial tumors.
  • CASE REPORT: We present a 17-year-old patient who suffered from an intraventricular malignant meningioma.
  • At the age of 2 years, acute lymphatic leukemia (common ALL [cALL]) was diagnosed and successfully treated with chemotherapy.
  • There was no cranial radiation therapy.
  • Histological diagnosis revealed a malignant papillary meningioma.
  • After removal of a recurrent meningioma 16 months later, he received local radiotherapy.
  • CONCLUSION: Pathogenetic mechanisms, treatment options, and prognosis of meningiomas and secondary malignancies of this age group are discussed.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Drug Therapy / methods. Humans. Magnetic Resonance Imaging / methods. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Dec 15;95(12):2562-70 [12467071.001]
  • [Cites] Pediatr Neurosurg. 2001 May;34(5):264-7 [11423779.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):598-601 [8831206.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] Childs Nerv Syst. 2001 Nov;17 (11):656-62 [11734983.001]
  • [Cites] Med Phys. 2001 Nov;28(11):2387-8 [11764047.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:247-54 [3628810.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):964-9 [11420471.001]
  • (PMID = 16456690.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg; 2002 Aug;97(2):341-6
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
  • In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas.
  • The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.
  • METHODS: Hydroxyurea was administered at a dosage of approximately 20 mg/kg/day to 11 women and nine men (median age 59 years, range 31-75 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple).
  • In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant.
  • Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery.
  • Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.
  • All patients were evaluable for response to therapy.
  • In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8-151 weeks), and two of these showed clinical improvement.
  • One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations.
  • In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks.
  • Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Progression. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / physiopathology. Meningioma / drug therapy. Meningioma / physiopathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / physiopathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Remission Induction. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186462.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


12. Qureshi AI: Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet; 2004 Mar 6;363(9411):804-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endovascular treatment of cerebrovascular diseases and intracranial neoplasms.
  • Endovascular treatment has emerged as a minimally invasive approach to treat cerebrovascular diseases and possibly intracranial neoplasms.
  • Practice patterns for selection of patients for endovascular treatment are continuously being modified on the basis of new information derived from clinical studies.
  • In this review, I discuss the various endovascular treatments for diseases such as ischaemic stroke, carotid and intracranial stenosis, intracranial aneurysms, arteriovenous malformations, malignant gliomas, and meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / therapy. Cerebrovascular Disorders / surgery. Cerebrovascular Disorders / therapy
  • [MeSH-minor] Angioplasty / methods. Carotid Stenosis / surgery. Carotid Stenosis / therapy. Catheterization / methods. Cerebral Angiography. Clinical Trials as Topic. Embolization, Therapeutic / methods. Fibrinolytic Agents. Glioma / drug therapy. Glioma / surgery. Glioma / therapy. Humans. Infusions, Intra-Arterial. Intracranial Aneurysm / surgery. Intracranial Aneurysm / therapy. Intracranial Arteriovenous Malformations / surgery. Intracranial Arteriovenous Malformations / therapy. Meningioma / drug therapy. Meningioma / surgery. Meningioma / therapy. Stents. Stroke / surgery. Stroke / therapy. Thrombolytic Therapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15016492.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  • [Number-of-references] 140
  •  go-up   go-down


13. Strassner C, Buhl R, Mehdorn HM: Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res; 2009 Jun;31(5):478-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
  • OBJECTIVE: Meningiomas are benign intracranial tumors growing from the arachnoid cap cells.
  • METHODS: Between 1991 and 2002, 463 patients with an intracranial meningioma were operated in the Department of Neurosurgery, University of Kiel, Kiel, Germany.
  • We compared the outcome of these patients after operation and the different methods of radiation therapy and chemotherapy with the data from Buhl (1994), who analysed 661 patients with intracranial meningioma who were operated on in the Department of Neurosurgery, University of Essen, Essen, Germany, between 1968 and 1988, to find out whether better methods of diagnosis like magnetic resonance imaging scans, magnetic resonance spectroscopy, post-operative radiation therapy and chemotherapy have an influence on the recurrence and outcome after surgical treatment.
  • Both studies underlined the preponderance of female patients for intracranial meningiomas.
  • The intracranial localization of the meningiomas was similar to the distribution of the histological subtypes and the rate of recurrence; only the malignant meningiomas showed a higher grade of recurrence in the last study.
  • Indications for post-operative radiation therapy were given earlier in the last study owing to the experience from the primary study.
  • The outcome of the patients after surgical removal was improving in the last years; the 30 day post-operative mortality after a primary operation on an intracranial meningioma decreased from 12.1 to 3%.
  • After removal of a recurrent meningioma, the mortality declined from 20 to 12.5%.
  • CONCLUSION: In the last 30 years, nothing important changed at the time of appearance of meningiomas, concerning the gender distribution and localisation as well as histological subtypes.
  • With better operating modalities and additional treatment with radiation and gamma knife, the mortality decreased significantly from 12 to 3% and the outcome of the patients is still improving, so that even elderly patients with intracranial meningioma can undergo surgical treatment with minor risks.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiosurgery. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500450.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Chamberlain MC, Blumenthal DT: Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother; 2004 Jul;4(4):641-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: diagnosis and treatment.
  • Most meningiomas (90%) are benign, 6% are atypical and a small proportion (2%) are malignant.
  • Most patients diagnosed with a meningioma undergo surgical resection to relieve neurological symptoms.
  • Advocates of stereotactic radiotherapy have suggested this therapy in lieu of surgery particularly in poor surgical risk patients, patients with meningiomas in eloquent or surgically inaccessible locations and in patients of advanced age.
  • When the meningioma is unresectable or all other treatments (e.g., surgery and radiotherapy) have failed, hormonal chemotherapy may be considered.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853583.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


15. Rockhill J, Mrugala M, Chamberlain MC: Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus; 2007;23(4):E1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: an overview of diagnosis and treatment.
  • Ninety percent of meningiomas are benign, 6% are atypical, and 2% are malignant.
  • Most patients in whom a meningioma is diagnosed undergo resection to relieve neurological symptoms.
  • Radiotherapy may be administered as either conventional external-beam radiation therapy or stereotactically by linear accelerator, Leksell Gamma Knife, or Cyberknife radiosurgery.
  • Advocates of stereo-tactic radiotherapy have suggested this therapy in lieu of surgery particularly in high-risk patients, those with meningiomas in eloquent or surgically inaccessible locations, and elderly patients.
  • When the meningioma is unresectable or all other treatments (surgery and radiotherapy) have failed, hormonal therapy or chemotherapy may be considered.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961033.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


16. Kempuraj D, Devi RS, Madhappan B, Conti P, Nazer MY, Christodoulou S, Reginald J, Suthinthirarajan N, Namasivayam A: T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol; 2004 Jan-Apr;17(1):57-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors.
  • It has been reported that nervous system and peripheral immune system communicate with each other and the peripheral immune status is depressed in some intracranial tumor (ICT) patients pre operatively.
  • Little is known about the immune status of intracranial tumor patients during the post operative survival period.
  • We thus investigated total T cells (CD 11+), helper/inducer (CD4+) T cells, suppressor/cytotoxic (CD8+) T cells, B cells (CD19+) and serum immunoglobulins in peripheral blood in certain ICT patients before and after treatment, and based on the histological type of the tumors.
  • Post treatment analysis were conducted 30 days after surgical removal of tumor tissue in benign brain tumor patients and 30 days after chemo therapy (CT)/radiotherapy (RT) following surgical removal of tumor tissue in malignant brain tumor patients.
  • Decreased CD11+, CD4+ and increased CD8+ T cell counts were observed in both benign and malignant tumor cases before treatment compared with control subjects.
  • After treatment, CD4+ T cell count increased and CD8+ T cell count decreased than their pre treatment levels.
  • Serum IgA and IgG levels were decreased in both benign and malignant brain tumor patients before treatment than in control subjects.
  • Serum IgM level has been increased in both benign and malignant tumor patients before and after treatment than in control subjects.
  • Anaplastic malignant astrocytoma, medulloblastoma and glioblastoma multiforme patients showed higher IgM level than astrocytoma, meningioma and ependymoma patients.
  • In conclusions, the depressed host cellular immunity in benign and malignant tumor patients before treatment may be due to the changes in CD4+ and CD8+ counts in addition to tumour specific immunosuppressive factors.
  • Treatment procedures such as surgery, CT and RT may play certain role in the post operative depressed immunosuppression in malignant tumor patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / immunology. Brain Neoplasms / pathology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Immunoglobulins / blood
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Analysis of Variance. Astrocytoma / drug therapy. Astrocytoma / immunology. Astrocytoma / pathology. Ependymoma / drug therapy. Ependymoma / immunology. Ependymoma / pathology. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Meningioma / drug therapy. Meningioma / immunology. Meningioma / pathology. Oligodendroglioma / drug therapy. Oligodendroglioma / immunology. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000867.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Immunoglobulins; 0 / Immunosuppressive Agents
  •  go-up   go-down


17. Jabbour SK, Zhang Z, Arnold D, Wharam MD: Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience. J Neurooncol; 2009 Jan;91(2):227-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience.
  • BACKGROUND: We reviewed the risk of second tumor (ST), both malignant and benign, in germinoma survivors followed at the Johns Hopkins Hospital (JHH).
  • METHODS: Between 1977 and 2002, 27 patients with intracranial germinoma were treated with radiation therapy (RT).
  • In the presence of competing events, a cumulative incidence function of ST was estimated using the minimal time interval from the date of diagnosis to the date of ST, date of death, or date of last follow-up.
  • RESULTS: Five patients (18%) developed a ST of which 4 (15%) were malignant.
  • One developed a benign falcine meningioma.
  • Current trials of chemotherapy and reduced RT dose and volume offer the prospect of a lower risk of treatment-induced ST.
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / radiotherapy. Child. Combined Modality Therapy. Female. Follow-Up Studies. Germinoma / radiotherapy. Humans. Incidence. Male. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1874-8 [2556586.001]
  • [Cites] Intern Med. 2000 Nov;39(11):920-4 [11065243.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):83-5 [15527112.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):410-3 [17475364.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):453-9 [16767718.001]
  • [Cites] Neuropediatrics. 2005 Apr;36(2):71-7 [15822019.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2833-9 [17602088.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):723-6 [10442196.001]
  • [Cites] Urol Oncol. 2001 Mar;6(2):49-52 [11166620.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):14-21 [2536126.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2741-2; author reply 2742 [17039496.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):511-8 [12738328.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):294-7 [17243137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1165-70 [15001260.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):771-2 [7962639.001]
  • [Cites] Ann Oncol. 2005 May;16(5):793-7 [15802277.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):126-34 [15895370.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):77-82 [16047364.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • (PMID = 18813873.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol; 2009 Mar;92(1):1-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
  • Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal.
  • Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed.
  • Antiprogesterone treatment can also be considered in recurrent benign meningiomas.
  • Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Meningeal Neoplasms / therapy. Meningioma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Clinical Trials as Topic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jun;68(2):131-40 [15218949.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Rev Neurol. 1997 Dec;25(148):2002-5 [9528047.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1865-74 [10815909.001]
  • [Cites] Eur J Cancer. 1991;27(11):1453-7 [1660295.001]
  • [Cites] J Clin Neurosci. 2008 Jun;15(6):721-2; author reply 722-3 [18406141.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):365-73; discussion 373-4 [7731518.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E10 [17961034.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):133-42 [11995814.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Feb;34(2):265-8 [17301541.001]
  • [Cites] Neurochirurgie. 2004 Sep;50(4):461-7 [15547484.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1109-20; discussion 1120-1 [17143245.001]
  • [Cites] Eur J Cancer. 1991;27(4):416-9 [1828169.001]
  • [Cites] Skull Base. 2006 Aug;16(3):157-60 [17268588.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:202-7 [7962466.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Jul;110(7):645-8 [18471956.001]
  • [Cites] Acta Neurol Scand. 1987 Jun;75(6):434-6 [2888257.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):187-92 [17525632.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):692-702; discussion 702-3 [10719866.001]
  • (PMID = 19023520.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 43
  •  go-up   go-down


19. Roser F, Nakamura M, Brandis A, Hans V, Vorkapic P, Samii M: Transition from meningeal melanocytoma to primary cerebral melanoma. Case report. J Neurosurg; 2004 Sep;101(3):528-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe the first case of an intracranial transition of a melanocytoma into a primary malignant melanoma within a short time.
  • The histological workup following subtotal tumor resection of the initial tumor had revealed the typical features of a fibrous melanocytic meningioma without increased proliferation.
  • Ten years after the patient had completed treatment for the melanocytic meningioma, control neuroimaging demonstrated growth of the residual tumor with compression of the brainstem.
  • At this time immunohistochemical examinations demonstrated melanocytic features (expression of vimentin, S100 protein, and melan A) of the lesion with focally increased proliferation (5% of Ki-67-positive cells) but no higher mitotic activity.
  • Pleomorphic changes and a focal high mitotic activity led to the diagnosis of a primary cerebral malignant melanoma.
  • Despite whole-brain and stereotactic radiation therapy as well as chemotherapy, the patient died 4 months after the last neuropathological diagnosis.
  • Although grossly resembling a meningioma, melanocytomas lack the former's histological and immunohistochemical features.
  • The biological behavior of a melanocytoma is variable and recurrence may happen after subtotal resection, but intracranial transition into a malignant melanoma has not been observed previously.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm, Residual / pathology. Nevus / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352613.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Braun B, Lange M, Oeckler R, Mueller MM: Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol; 2004 Jun;68(2):131-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hematopoietic growth factors granulocyte- and granulocyte-macrophage colony stimulating factor (G-CSF and GM-CSF) are nowadays widely used in routine cancer therapies as potent factors to control radiation and chemotherapy induced neutropenia, a side effect that frequently endangers the success of tumor therapies.
  • We were interested in the expression and potential role of both factors in human meningiomas, tumors of arachnoidal origin that account for about 20% of all primary intracranial tumors.
  • Therefore, we analyzed immunohistochemically the protein expression of G-CSF, GM-CSF and their respective receptors in 30 meningioma tissues of different malignancy and histopathological type.
  • Both factors and receptors were not expressed in the corresponding normal tissue.
  • In addition, a strong perivascular expression of G-CSF was associated with a highly vascularized tumor type.
  • Thus, expression of both G-CSF and GM-CSF is associated with the expression of proliferation vascularization, two markers of an increasingly malignant tumor phenotype, suggesting a contribution of both factors to tumor progression.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / metabolism. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / pathology. Meningioma / blood supply. Meningioma / pathology. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] Am J Hematol. 1995 Jul;49(3):207-15 [7541602.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):477-88 [7510132.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Oncogene. 1993 Feb;8(2):231-6 [8426734.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] Int J Cancer. 1992 Jul 30;51(6):873-7 [1353485.001]
  • [Cites] Arch Dermatol Res. 1995;287(3-4):231-6 [7598526.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6264-7 [2205378.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Eur J Cancer. 1995;31A(3):302-7 [7540401.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3438-43 [7542171.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9253-7 [3057504.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2471-508 [7964965.001]
  • [Cites] Clin Exp Metastasis. 1996 Sep;14(4):351-7 [8878409.001]
  • [Cites] Cell. 2000 Nov 22;103(5):745-55 [11114331.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2791-808 [1720034.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3139-44 [8319222.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1557-67 [10550313.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):780-9 [10597195.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Head Neck. 1997 Jul;19(4):351-6 [9213115.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4141-7 [9307305.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):155-62 [10619499.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2611-4 [9205065.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):794-800 [9485037.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):905-6; discussion 907 [7688363.001]
  • [Cites] Cytokines Cell Mol Ther. 1998 Jun;4(2):113-20 [9681250.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):949-62 [9060833.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):19-26 [12125963.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1724-31 [8400229.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1413-9 [1372187.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):383-7 [10985899.001]
  • [Cites] Hematol Pathol. 1992;6(3):105-24 [1429340.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):541-5 [8123485.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):803-8 [7540696.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1310-3 [7682568.001]
  • [Cites] J Clin Invest. 1991 Mar;87(3):986-95 [1705569.001]
  • [Cites] J Neurooncol. 1993 Sep;17(3):183-90 [8164055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):845-50 [7688362.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1146-53 [1659742.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):78-84 [9935235.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1065-74 [8133992.001]
  • (PMID = 15218949.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


21. Knox MK, Ménard C, Mason WP: Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri. J Neurooncol; 2010 Oct;100(1):145-9
Genetic Alliance. consumer health - Gliomatosis Cerebri.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptomeningeal gliomatosis is a known, yet uncommon, complication of malignant gliomas.
  • For both entities, limited data exist to guide treatment and prognosis is poor.
  • We describe the case of a patient who presented with symptoms of increased intracranial pressure and diffuse leptomeningeal enhancement in the brain and spinal cord on MRI.
  • After a period of surveillance, intraparenchymal lesions developed in association with widespread diffuse infiltration.
  • Initial treatment consisted of six cycles of temozolomide chemotherapy.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Neoplasms, Neuroepithelial / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1998 Oct;50(4):356-62; discussion 362 [9817460.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):163-8 [10619500.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):533-40 [2797391.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):201-5 [16200347.001]
  • [Cites] Neurology. 1992 Jan;42(1):252-4 [1310353.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):324-29; discussion 330 [12535360.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):247-53 [12533659.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):209-16 [17031563.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):161-7 [9524095.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):354-6 [15277636.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):223-226 [11154809.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):275-83 [8360714.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):73-82 [19353837.001]
  • [Cites] Acta Neurol Scand. 1989 Feb;79(2):133-9 [2711819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] J Clin Neurosci. 2006 Feb;13(2):298-301 [16431108.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 20146082.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Payen JF, Faillot T, Audibert G, Vergnes MC, Bosson JL, Lestienne B, Bernard C, Bruder N: [Thromboprophylaxis in neurosurgery and head trauma]. Ann Fr Anesth Reanim; 2005 Aug;24(8):921-7
MedlinePlus Health Information. consumer health - Head Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific risk factors in neurosurgery are: a motor deficit, a meningioma or malignant tumour, a large tumour, age over 60 years, surgery lasting more than 4 hours, a chemotherapy.
  • A postoperative prophylaxis with a LMWH does not seem to increase the risk of intracranial bleeding (grade C).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006086.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


23. Uzuka T, Takahashi H, Tanaka R, Nishibori T, Tsukada H, Gejyo F: [Pneumocystis carinii pneumonia complicating brain tumor]. No Shinkei Geka; 2004 Feb;32(2):127-33
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in Japan it is not widely recognized that primary brain tumor patients who are receiving steroid therapy become susceptible to Pneumocystis carinii pneumonia (PCP).
  • Underlying diseases included malignant glioma in 9 patients, malignant lymphoma in 2 patients and meningioma in one patient.
  • Radiation therapies were administered with 20 to 60 Gy (mean 52.9 Gy) except in one patient.
  • Chemotherapy was performed with ranimustine in 4 malignant glioma patients and with methotrexate in 2 malignant lymphoma patients.
  • The duration of steroid treatment at the onset of PCP in these patients ranged from 41 to 79 days (mean 61.4 days).
  • Six patients (50%) died of PCP despite appropriate antibiotic therapy and 2 patients needed intensive therapy with a respirator.
  • ; chest X ray and CT image) is indicated in patients with brain tumors, and prophylaxis against PCP might be needed for patients with intracranial neoplasms and who are also receiving high-dose and long-term steroid treatment.
  • [MeSH-major] Brain Neoplasms / drug therapy. Pneumonia, Pneumocystis / etiology. Prednisolone / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15031973.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


24. Teixeira MJ, Lepski G, Correia C, Aguiar PH: Interstitial irradiation for CNS lesions. Stereotact Funct Neurosurg; 2003;81(1-4):24-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we investigated the efficacy of brachytherapy in the treatment of 138 patients with intracranial neoplasms of the CNS.
  • Of the total number of patients, 50 presented with glioblastoma multiforme, 45 presented with low-grade glioma, 19 presented with anaplastic astrocytoma, 23 presented with metastases and 1 presented with meningioma.
  • During the execution of this study, seeds of 125I (10-20 mCi) were inserted into the lesions to aim the irradiation at a low dose of 60 Gy in the margin of benign lesions or 1 cm beyond the radiological border of malignant lesions, which were visualized on CT scan.
  • The results of this procedure were evaluated in terms of the survival rates, which were assessed by Kaplan-Meier curves.
  • Significant relationships were not observed between the volume and location of the lesions, the whole-brain radiotherapy and chemotherapy, and the survival time of the patients.
  • A low Karnofsky Index score and older age were associated with a short survival time.
  • In light of the above, it was concluded that interstitial irradiation is a safe and effective method of treatment for brain tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14742960.001).
  • [ISSN] 1011-6125
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement